AWM
IMMU

AE Wealth Management’s Immunomedics Inc IMMU Stock Holding History

AE Wealth Management’s Portfolio IMMU Stock Details IMMU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-50,000
Closed -$699K – 475
2017
Q3 		$699K Hold
50,000
– – 0.06% 198
2017
Q2 		$442K Buy
+50,000
New +$351K 0.05% 247

Other funds holding IMMU

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AE Wealth Management's IMMU Position: Q4 2017 in Review

AE Wealth Management sold out of Immunomedics Inc (IMMU) in Q4 2017, closing a stake of 50,000 shares — an estimated $699K sold.

AE Wealth Management first reported a position in IMMU in Q2 2017 and held it in 2 quarters. The position peaked at $699K in Q3 2017. 157 funds tracked by Wall St. Rank hold IMMU as of Q4 2017.

  • AE Wealth Management reported no remaining Immunomedics Inc position as of Q4 2017 after selling out during the quarter.
  • AE Wealth Management sold 50,000 Immunomedics Inc shares in Q4 2017, an estimated $699K.
  • AE Wealth Management first reported a position in Immunomedics Inc in Q2 2017 and held it in 2 quarters.
  • AE Wealth Management's Immunomedics Inc position peaked at $699K in Q3 2017.
  • 157 funds tracked by Wall St. Rank held Immunomedics Inc as of Q4 2017.

Based on AE Wealth Management's 13F filing for Q4 2017, filed 6 Feb 2018.